The Rising Role of Liquid Biopsy in the Cancer biomarker Market
Liquid biopsy is revolutionizing the Cancer biomarker Market. By detecting circulating tumor DNA and other markers in blood samples, it provides a non-invasive method for cancer diagnosis and monitoring.
This innovation reduces reliance on traditional biopsies and allows real-time tracking of tumor evolution. With growing clinical adoption, liquid biopsy is set to expand biomarker applications significantly.
Market Outlook: Estimated at USD 15.9 billion in 2022, the cancer biomarker market will grow to USD 27.8 billion by 2030, advancing at 9.8% CAGR.